L-PHENYLALANINE DERIVATIVES AND THEIR USE AS INTEGRIN ANTAGONISTS
申请人:AstraZeneca AB
公开号:EP2091916A2
公开(公告)日:2009-08-26
[EN] L-PHENYLALANINE DERIVATIVES<br/>[FR] DERIVES DE L-PHENYLALANINE
申请人:ASTRAZENECA AB
公开号:WO2007060408A2
公开(公告)日:2007-05-31
[EN] The present invention relates to compounds that inhibit of a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to compounds that inhibit a5b1, and also that exhibit appropriate selectivity profile(s) against other integrins. [FR] L'invention concerne des composés qui inhibent la fonction a5b1, des procédés de préparation de ceux-ci, des compositions pharmaceutiques les contenant en tant qu'ingrédient actif, leur utilisation en tant que médicaments et leur utilisation dans la fabrication de médicaments servant à traiter des animaux à sang chaud, par exemple des humains, qui souffrent de maladies dans lesquelles une composante vasculaire ou d'angiogenèse significative est présente, de type tumeurs solides. L'invention concerne également des composés qui inhibent la fonction a5b1, et qui présentent un ou des profils de sélectivité appropriés contre d'autres intégrines.
WO2007/60408
申请人:——
公开号:——
公开(公告)日:——
L-Phenylalanine Derivatives
申请人:Barry Simon Thomas
公开号:US20090137601A1
公开(公告)日:2009-05-28
The present invention relates to compounds that inhibit of a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to compounds that inhibit a5b1, and also that exhibit appropriate selectivity profile(s) against other integrins.